Ar­bu­tus re­gains rights to he­pati­tis B as­set in Chi­na; Forte’s $75M of­fer­ing

Plus, news about the No­vo Nordisk Foun­da­tion, As­sem­bly Bio­sciences, Cidara Ther­a­peu­tics, Mi­novia and Celyad On­col­o­gy:

Ar­bu­tus reac­quires Chi­na rights to he­pati­tis B can­di­date: The com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER